Pre-Made Acazicolcept Biosimilar, Fusion Protein targeting CD28 fused with human IGHG1 Fc (Fragment constant) via a peptidyl linker: Recombinant therapeutic protein targeting Tp44 for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Acazicolcept Biosimilar, Fusion Protein targeting CD28 fused with human IGHG1 Fc (Fragment constant) via a peptidyl linker: Recombinant therapeutic protein targeting Tp44 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Uncontrolled immune response with T cell activation has a key role in the pathogenesis of systemic sclerosis (SSc), a disorder that is characterized by generalized fibrosis affecting particularly the lungs and skin. CD28 and ICOS are critical costimulatory receptors that together regulate the activation, differentiation and proliferation of a range of T cells that may play a role in autoimmune and inflammatory disease. Acazicolcept is a single protein domain, or vIgD (Variant Ig Domain) based on a human inducible T cell costimulator ligand (ICOSL) that is capable of binding to both CD28 and ICOS. By simultaneously blocking these two key costimulatory pathways, acazicolcept has the potential to improve clinical outcomes in patients suffering from severe autoimmune and inflammatory disease
| Products Name (INN Index) | Pre-Made Acazicolcept Biosimilar, Fusion Protein targeting CD28 fused with human IGHG1 Fc (Fragment constant) via a peptidyl linker: Recombinant therapeutic protein targeting Tp44 |
|---|---|
| INN Name | acazicolcept |
| Target | CD28 |
| Format | Fusion Protein |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | Fusion – [ICOSLG (inducible T-cell co- stimulator ligand, B7H2, B7-H2, ICOS-L, B7-related protein 1, B7RP1, B7RP-1, B7 homolog 2, B7 homologue 2, GL50, KIAA0653, CD275) N-terminal fragment (1-122)]2 |
| VD LC | Fusion – [ICOSLG (inducible T-cell co- stimulator ligand, B7H2, B7-H2, ICOS-L, B7-related protein 1, B7RP1, B7RP-1, B7 homolog 2, B7 homologue 2, GL50, KIAA0653, CD275) N-terminal fragment (1-122)]2 |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | Alpine?Immune Sciences (Seattle WA USA) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | CD28 |
| Package |
